Alnylam Pharmaceuticals, Inc.
DE ˙ XTRA ˙ US02043Q1076
251,80 € ↑6,70 (2,73%)
2026-06-03
DEL PRIS
SecurityDE:DUL / Alnylam Pharmaceuticals, Inc.
InstitutionAmalgamated Bank
Latest Disclosed Ownership9,937 shares
Latest Disclosed Value $ 3,288
Amalgamated Bank reports 6.95% decrease in ownership of DUL / Alnylam Pharmaceuticals, Inc.

On May 8, 2026 - Amalgamated Bank filed a 13F-HR form disclosing ownership of 9,937 shares of Alnylam Pharmaceuticals, Inc. (DE:DUL) valued at $2,839,001 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 5, 2026 disclosing 10,679 shares of Alnylam Pharmaceuticals, Inc.. This represents a change in shares of -6.95% during the quarter. The current value of the position is $2,502,137 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-08 2026-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 9,937 -742 -6.95 3 -25.00 0.0252
2026-02-05 2025-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 10,679 535 5.27 4 0.00 0.0307
2025-10-29 2025-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 10,144 676 7.14 5 33.33 0.0331
2025-08-04 2025-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 9,468 615 6.95 3 50.00 0.0238
2025-04-25 2025-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 8,853 369 4.35 2 100.00 0.0205
2025-02-04 2024-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 8,484 205 2.48 2 -50.00 0.0164
2024-10-30 2024-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 8,279 -75 -0.90 2 0.00 0.0188
2024-08-12 2024-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 8,354 301 3.74 2 100.00 0.0173
2024-04-23 2024-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 8,053 -3,306 -29.10 1 -50.00 0.0103
2024-02-06 2023-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 11,359 -1,387 -10.88 2 0.00 0.0173
2023-11-08 2023-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 12,746 -400 -3.04 2 0.00 0.0192
2023-08-11 2023-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 13,146 -932 -6.62 2 0.00 0.0202
2023-05-02 2023-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 14,078 211 1.52 3 -33.33 0.0240
2023-02-10 2022-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 13,867 387 2.87 3 -99.89 0.0294
2022-11-09 2022-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 13,480 213 1.61 2,698 39.43 0.0260
2022-08-15 2022-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 13,267 -88 -0.66 1,935 -11.28 0.0180
2022-08-25 2022-03-31 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 13,355 2,877 27.46 2,181 22.73 0.0169
2022-06-30 2022-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 13,355 2,877 2,181 0.0173
2022-02-15 2021-12-31 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 10,478 3,602 52.39 1,777 36.90 0.0131
2022-02-15 2021-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 10,478 3,602 1,777 0.0131
2021-10-29 2021-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 6,876 -1,068 -13.44 1,298 -3.64 0.0110
2021-08-16 2021-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 7,944 2,264 39.86 1,347 67.96 0.0108
2021-05-13 2021-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 5,680 -338 -5.62 802 2.56 0.0301
2021-02-12 2020-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 6,018 -88 -1.44 782 -12.04 0.0296
2020-10-30 2020-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 6,106 -43 -0.70 889 -2.41 0.0387
2020-08-10 2020-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 6,149 -20,994 -77.35 911 -69.17 0.0422
2020-05-13 2020-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 27,143 -331 -1.20 2,955 -6.61 0.0722
2020-02-13 2019-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 27,474 1,506 5.80 3,164 51.53 0.0582
2019-11-13 2019-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 25,968 2,888 12.51 2,088 24.66 0.0439
2019-08-14 2019-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 23,080 2,109 10.06 1,675 -14.54 0.0391
2019-05-15 2019-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 20,971 1,401 7.16 1,960 37.35 0.0475
2019-02-15 2018-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 19,570 6,795 53.19 1,427 27.64 0.0404
2018-11-14 2018-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 12,775 -7,645 -37.44 1,118 -44.41 0.0276
2018-07-18 2018-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 20,420 2,080 11.34 2,011 -7.92 0.0491
2018-05-22 2018-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 18,340 1,228 7.18 2,184 0.46 0.0579
2018-02-13 2017-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 17,112 2,070 13.76 2,174 23.03 0.0588
2017-11-09 2017-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 15,042 1,084 7.77 1,767 58.76 0.0550
2017-08-10 2017-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 13,958 3,052 27.98 1,113 99.11 0.0365
2017-05-12 2017-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 10,906 -2,055 -15.86 559 15.26 0.0278
2017-02-14 2016-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 12,961 1,392 12.03 485 -38.14 0.0219
2016-11-15 2016-09-30 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 11,569 4 0.03 784 -8.73 0.0455
2016-08-16 2016-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 11,565 11,565 0.00 859 0.0497
2015-11-04 2015-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 0 -2,224 -100.00 0 -100.00
2015-07-10 2015-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 2,224 -4,968 -69.08 267 -64.45 0.0262
2015-04-22 2015-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 7,192 7,192 0.00 751 0.0917
2015-01-29 2014-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 0 -6,357 -100.00 0 -100.00
2014-11-14 2014-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 6,357 79 1.26 496 24.94 0.0738
2014-08-11 2014-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 6,278 601 10.59 397 4.20 0.0599
2014-05-12 2014-03-31 13F ALNYLAM PHARMACEUTICALS INC COM COM 02043Q107 5,677 -51 -0.89 381 3.53 0.0656
2014-02-13 2013-12-31 13F ALNYLAM PHARMACEUTICALS INC COM COM 02043Q107 5,728 5,728 368 0.0625
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.